Editorial & Advertiser disclosure

Global Banking & Finance Review® is an online platform offering news, analysis, and opinion on the latest trends, developments, and innovations in the banking and finance industry worldwide. The platform covers a diverse range of topics, including banking, insurance, investment, wealth management, fintech, and regulatory issues. The website publishes news, press releases, opinion and advertorials on various financial organizations, products and services which are commissioned from various Companies, Organizations, PR agencies, Bloggers etc. These commissioned articles are commercial in nature. This is not to be considered as financial advice and should be considered only for information purposes. It does not reflect the views or opinion of our website and is not to be considered an endorsement or a recommendation. We cannot guarantee the accuracy or applicability of any information provided with respect to your individual or personal circumstances. Please seek Professional advice from a qualified professional before making any financial decisions. We link to various third-party websites, affiliate sales networks, and to our advertising partners websites. When you view or click on certain links available on our articles, our partners may compensate us for displaying the content to you or make a purchase or fill a form. This will not incur any additional charges to you. To make things simpler for you to identity or distinguish advertised or sponsored articles or links, you may consider all articles or links hosted on our site as a commercial article placement. We will not be responsible for any loss you may suffer as a result of any omission or inaccuracy on the website.

Home > Research Reports > Ibuprofen API Market Product Type, Industry Outlook, Current Status, COVID 19 impact on Market Share 2029

Research Reports

Ibuprofen API Market Product Type, Industry Outlook, Current Status, COVID 19 impact on Market Share 2029

Published by mark itwired

Posted on August 3, 2021

12 min read

Last updated: January 21, 2026

Dimas Yusuf discusses Sucor Asset Management's innovative vision - Global Banking & Finance Review — In this exclusive interview, Dimas Yusuf, Investment Director at Sucor Asset Management, shares insights on resilience and innovation in finance, highlighting the firm's strategic vision for the future.

The global ibuprofen API market surpassed US$ 572.9 Mn in 2019 and is set for a stable growth outlook over the course of 2019 – 2029, as per the findings of a new Future Market Insights (FMI) study. The primary factors for growth of the Ibuprofen API market include continuous demand for low-cost non-steroidal anti-inflammatory drugs (NSAID), and scale and age of manufacturing facilities.

Increasing API drug shortages and assembling task force to overcome these problems, emergence of cost-effective drug manufacturers in various countries and supply of API drugs, primarily in developing countries, are further driving ibuprofen API market growth.

The pharmaceutical API industry is witnessing a substantial crunch in supply and demand of Ibuprofen API, halted production from major ibuprofen API manufactures, supply chain disruption in china further led by declining sale in India. The volatility in Ibuprofen API is due to factors such as lower number of competitors, reduced utilization ratio, lower margin level, new higher-value opportunities in complex combinations and high-grade API, pace of facility inspection by FDA, and ramping up production capacity of through mergers and consolidation.

FMI Analyses the COVID-19 Impact on Market

FMI’s analysis suggests that the ongoing COVID-19 pandemic is having adverse impacts on market growth. Wuhan, China is the hub of API supplies. The region is the epicenter of the coronavirus outbreak, as such, it has temporarily halted its manufacturing facilities. Further, China is the prominent or the sole supplier of APIs including, penicillin and erythromycin, in the world. Manufacturers and distributors in the country are blaming logistical barriers and labor scarcity due to the COVID-19 pandemic for delay in production and transportation.

Request For Report Sample @ https://www.futuremarketinsights.com/reports/sample/rep-gb-11260

Key Takeaways of Ibuprofen API Market Study

Greater focus on relieving pressure of supply chain due to demand gap is being tackled by ramping up production capacity, up-scaling is the fundamental strategy outlined for meeting demand in the Ibuprofen API space.
Majority of the anti-inflammatory drugs are manufactured in Asia, especially in China and India. Approximately 80% of the total anti-inflammatory APIs are manufactured in India and China and most of the APIs manufactured in these countries are outsourced to other developed regions – North America and Europe.
High upfront cost and lower margin level in Ibuprofen API have resulted in 20-30% price spike in final drug formulations and lower sales in previous year.
The market for Ibuprofen API is consolidated in nature, with leading manufacturers holding around 90% of market value as 90%. Hence, growing interest of CMOs and large-scale API manufacturers are anticipated to boost the value creation of ibuprofen API market.
Higher volume handling by Contract Manufacturing Organizations in comparison to pharmaceutical companies and amid higher production capabilities and price advantage over pharmaceutical companies are expected to generate significant revenue pockets.
Expanding patient pool consuming non-controlled drugs as OTC are also responsible for the growth of in-house ibuprofen API consumption in South and East Asia.

Lower labor cost, abundant availability of raw materials required to ibuprofen API are among the key factors fueling the growth of ibuprofen API market in South Asia. In addition, favorable regulatory support to establish ibuprofen API manufacturing businesses, lower taxation policies are boosting the growth of East and South Asia ibuprofen API market.

Capacity Expansion, and Strategic Mergers & Acquisitions to Widen Regional Presence

Leading players in ibuprofen API market – SI Group, Inc., BASF SE, Hubei Biocause Phamaceutical Co., Ltd. (BIOCAUSE Inc.), IOL Chemicals, Sino-US Zibo Xinhua-Perrigo Pharmaceutical Co., Ltd., and Solara Active Pharma Sciences Limited – are focusing on business expansions by mergers, joint ventures, distribution agreements and capturing the untapped potential of the Ibuprofen API market.

In 2018, IOL Chemicals, the largest Indian Ibuprofen API manufacturer, expanded its production capacity to 12000 MT from previous capacity of 7500 MT. With the increased capacity, IOL Chemicals is filling the demand-supply gap that is rising due to stringent regulatory reform in China. This move can further benefit the Indian manufactures looking to strengthen their foothold in Ibuprofen API market.
The acquisition by Solara Active Pharma Sciences Limited in 2018 of the Ibuprofen API assets of Strides and Sequent enabled the company to capture the portfolio of niche segments of the Ibuprofen API market.
The joint venture between Granules India Ltd (GIL) and Hubei Biocause Heilen Pharmaceutical Co. Ltd. have a production facility in Jingmen, China. In recent discussion, Granules India Ltd (GIL) is planning to part out from the joint venture.

Additionally, current acquisitions are focused on capacity expansion, and manufacturing capabilities of existing Ibuprofen API players in order to gain competitiveness and accelerate revenue growth in the market landscape.

More Valuable Insights on Ibuprofen API Market

Future Market Insights brings the comprehensive research report on forecasted revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the segments from 2014 to 2029. The global Ibuprofen API market is segmented in detail to cover every aspect of the market and present a complete market intelligence approach to the reader. The study provides compelling insights on Ibuprofen API market on basis of by end user (Contract Manufacturing Organization and Pharmaceutical Companies), across seven major regions.

Speak to Analyst, Questions Related To Report @ https://www.futuremarketinsights.com/ask-question/rep-gb-11260

Reasons to Buy the report

We provide authentic and detailed an analysis on various market trends to enable businesses to make informed and beneficial decisions to attain competitive edge over key players.
Our analysts provide detailed market segmentation along with meaningful insights and extensive reports that other companies fail to include.
The report includes accurate analysis of the market and the current developing trends affecting the growth. FMI speaks to stakeholders across the spectrum, including C-level executives, distributors, product manufacturers, industry experts. This ensures that the data collected is from highly reliable sources.

FMI’s Healthcare Research Reports:

About FMI

Future Market Insights (FMI) is a leading provider of market intelligence and consulting services, serving clients in over 150 countries. FMI is headquartered in Dubai, the global financial capital, and has delivery centers in the U.S. and India. FMI’s latest market research reports and industry analysis help businesses navigate challenges and make critical decisions with confidence and clarity amidst breakneck competition. Our customized and syndicated market research reports deliver actionable insights that drive sustainable growth. A team of expert-led analysts at FMI continuously tracks emerging trends and events in a broad range of industries to ensure that our clients prepare for the evolving needs of their consumers.

Contact

Mr. Abhishek Budholiya

Unit No: AU-01-H Gold Tower (AU), Plot No: JLT-PH1-I3A,

Jumeirah Lakes Towers, Dubai,

United Arab Emirates

MARKET ACCESS DMCC Initiative

For Sales Enquiries: sales@futuremarketinsights.com

For Media Enquiries: press@futuremarketinsights.com

Press Release: https://www.futuremarketinsights.com/press-release/ibuprofen-api-market

The global ibuprofen API market surpassed US$ 572.9 Mn in 2019 and is set for a stable growth outlook over the course of 2019 – 2029, as per the findings of a new Future Market Insights (FMI) study. The primary factors for growth of the Ibuprofen API market include continuous demand for low-cost non-steroidal anti-inflammatory drugs (NSAID), and scale and age of manufacturing facilities.

Increasing API drug shortages and assembling task force to overcome these problems, emergence of cost-effective drug manufacturers in various countries and supply of API drugs, primarily in developing countries, are further driving ibuprofen API market growth.

The pharmaceutical API industry is witnessing a substantial crunch in supply and demand of Ibuprofen API, halted production from major ibuprofen API manufactures, supply chain disruption in china further led by declining sale in India. The volatility in Ibuprofen API is due to factors such as lower number of competitors, reduced utilization ratio, lower margin level, new higher-value opportunities in complex combinations and high-grade API, pace of facility inspection by FDA, and ramping up production capacity of through mergers and consolidation.

FMI Analyses the COVID-19 Impact on Market

FMI’s analysis suggests that the ongoing COVID-19 pandemic is having adverse impacts on market growth. Wuhan, China is the hub of API supplies. The region is the epicenter of the coronavirus outbreak, as such, it has temporarily halted its manufacturing facilities. Further, China is the prominent or the sole supplier of APIs including, penicillin and erythromycin, in the world. Manufacturers and distributors in the country are blaming logistical barriers and labor scarcity due to the COVID-19 pandemic for delay in production and transportation.

Request For Report Sample @ https://www.futuremarketinsights.com/reports/sample/rep-gb-11260

Key Takeaways of Ibuprofen API Market Study

Greater focus on relieving pressure of supply chain due to demand gap is being tackled by ramping up production capacity, up-scaling is the fundamental strategy outlined for meeting demand in the Ibuprofen API space.
Majority of the anti-inflammatory drugs are manufactured in Asia, especially in China and India. Approximately 80% of the total anti-inflammatory APIs are manufactured in India and China and most of the APIs manufactured in these countries are outsourced to other developed regions – North America and Europe.
High upfront cost and lower margin level in Ibuprofen API have resulted in 20-30% price spike in final drug formulations and lower sales in previous year.
The market for Ibuprofen API is consolidated in nature, with leading manufacturers holding around 90% of market value as 90%. Hence, growing interest of CMOs and large-scale API manufacturers are anticipated to boost the value creation of ibuprofen API market.
Higher volume handling by Contract Manufacturing Organizations in comparison to pharmaceutical companies and amid higher production capabilities and price advantage over pharmaceutical companies are expected to generate significant revenue pockets.
Expanding patient pool consuming non-controlled drugs as OTC are also responsible for the growth of in-house ibuprofen API consumption in South and East Asia.

Lower labor cost, abundant availability of raw materials required to ibuprofen API are among the key factors fueling the growth of ibuprofen API market in South Asia. In addition, favorable regulatory support to establish ibuprofen API manufacturing businesses, lower taxation policies are boosting the growth of East and South Asia ibuprofen API market.

Capacity Expansion, and Strategic Mergers & Acquisitions to Widen Regional Presence

Leading players in ibuprofen API market – SI Group, Inc., BASF SE, Hubei Biocause Phamaceutical Co., Ltd. (BIOCAUSE Inc.), IOL Chemicals, Sino-US Zibo Xinhua-Perrigo Pharmaceutical Co., Ltd., and Solara Active Pharma Sciences Limited – are focusing on business expansions by mergers, joint ventures, distribution agreements and capturing the untapped potential of the Ibuprofen API market.

In 2018, IOL Chemicals, the largest Indian Ibuprofen API manufacturer, expanded its production capacity to 12000 MT from previous capacity of 7500 MT. With the increased capacity, IOL Chemicals is filling the demand-supply gap that is rising due to stringent regulatory reform in China. This move can further benefit the Indian manufactures looking to strengthen their foothold in Ibuprofen API market.
The acquisition by Solara Active Pharma Sciences Limited in 2018 of the Ibuprofen API assets of Strides and Sequent enabled the company to capture the portfolio of niche segments of the Ibuprofen API market.
The joint venture between Granules India Ltd (GIL) and Hubei Biocause Heilen Pharmaceutical Co. Ltd. have a production facility in Jingmen, China. In recent discussion, Granules India Ltd (GIL) is planning to part out from the joint venture.

Additionally, current acquisitions are focused on capacity expansion, and manufacturing capabilities of existing Ibuprofen API players in order to gain competitiveness and accelerate revenue growth in the market landscape.

More Valuable Insights on Ibuprofen API Market

Future Market Insights brings the comprehensive research report on forecasted revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the segments from 2014 to 2029. The global Ibuprofen API market is segmented in detail to cover every aspect of the market and present a complete market intelligence approach to the reader. The study provides compelling insights on Ibuprofen API market on basis of by end user (Contract Manufacturing Organization and Pharmaceutical Companies), across seven major regions.

Speak to Analyst, Questions Related To Report @ https://www.futuremarketinsights.com/ask-question/rep-gb-11260

Reasons to Buy the report

We provide authentic and detailed an analysis on various market trends to enable businesses to make informed and beneficial decisions to attain competitive edge over key players.
Our analysts provide detailed market segmentation along with meaningful insights and extensive reports that other companies fail to include.
The report includes accurate analysis of the market and the current developing trends affecting the growth. FMI speaks to stakeholders across the spectrum, including C-level executives, distributors, product manufacturers, industry experts. This ensures that the data collected is from highly reliable sources.

FMI’s Healthcare Research Reports:

About FMI

Future Market Insights (FMI) is a leading provider of market intelligence and consulting services, serving clients in over 150 countries. FMI is headquartered in Dubai, the global financial capital, and has delivery centers in the U.S. and India. FMI’s latest market research reports and industry analysis help businesses navigate challenges and make critical decisions with confidence and clarity amidst breakneck competition. Our customized and syndicated market research reports deliver actionable insights that drive sustainable growth. A team of expert-led analysts at FMI continuously tracks emerging trends and events in a broad range of industries to ensure that our clients prepare for the evolving needs of their consumers.

Contact

Mr. Abhishek Budholiya

Unit No: AU-01-H Gold Tower (AU), Plot No: JLT-PH1-I3A,

Jumeirah Lakes Towers, Dubai,

United Arab Emirates

MARKET ACCESS DMCC Initiative

For Sales Enquiries: sales@futuremarketinsights.com

For Media Enquiries: press@futuremarketinsights.com

Press Release: https://www.futuremarketinsights.com/press-release/ibuprofen-api-market